貨號：GS40102

Briquilimab (formerly known as JSP191) is a monoclonal antibody in clinical development as a conditioning agent for stem cell transplants and gene therapies. It works by selectively depleting blood-forming stem cells in the bone marrow to create space for new, healthy donor or gene-corrected stem cells to engraft. Unlike traditional chemotherapy- or radiation-based conditioning, Briquilimab is designed to be more targeted. It achieved an important milestone by being granted Breakthrough Therapy Designation by the U.S. FDA in 2023 for use in patients with severe combined immunodeficiency (SCID) undergoing stem cell transplantation.